RTP Mobile Logo
Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer
Released November 2019

A special audio program developed from an independent satellite symposium held during the ASTRO 2019 Annual Meeting. Featuring perspectives from moderator Dr Corey J Langer and faculty members Drs Shruti Jolly, Billy Wiseman Loo Jr and Jyoti D Patel. (Audio Program)

CE Disclosures and Faculty Information

    This activity is intended for radiation oncologists, medical oncologists, oncology fellows and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

    Non-small cell lung cancer (NSCLC) accounts for 84% of all cases of lung cancer, and within that population approximately one third of patients present with locally advanced Stage III disease. Expected 5-year survival rates for these patients range from 36% (Stage IIIA) to 13% (Stage IIIC). Therefore, the clinical care of these individuals remains one of the major challenges faced in solid tumor oncology. Recent breakthroughs in disease management for these patients have led to the advent of new treatment modalities, including the use of immunotherapy. But while immune checkpoint inhibitors have reshaped the management of locally advanced lung cancer, a number of controversies and questions remain with regard to the current application and future role of these agents in clinical practice.

    This CME program, developed from the proceedings of a satellite symposium held during the 2019 ASTRO Annual Meeting, features discussions with leading lung cancer investigators regarding the role of immune checkpoint inhibitors in the management of locally advanced NSCLC. By providing information on important developments, this activity will assist medical oncologists and other healthcare professionals to address uncertainties in the care of patients with this disease.


    • Understand the biologic basis for the investigation of immune checkpoint inhibitors in combination with chemoradiation therapy for nonmetastatic NSCLC.
    • Appreciate the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after concurrent chemoradiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
    • Consider the available data and investigator perspectives regarding the efficacy of immune checkpoint inhibitors for patients with locally advanced NSCLC with or without targetable mutations.
    • Recognize immune-related adverse events associated with the use of immune checkpoint inhibitors, and offer supportive strategies to minimize and/or manage these toxicities.
    • Recall emerging data with novel approaches and strategies using immune checkpoint inhibitors for patients with NSCLC, and consider how this information may be applied in future clinical practice.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASTRO19/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:


    Corey J Langer, MD
    Director of Thoracic Oncology
    Abramson Cancer Center
    Professor of Medicine
    Perelman School of Medicine
    University of Pennsylvania
    Philadelphia, Pennsylvania

    Advisory Committee and Consulting Agreements: AbbVie Inc, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Lilly, Merck, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Advantage Pharmaceuticals, GlaxoSmithKline, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc, Incyte Corporation, Lilly, SWOG.


    Shruti Jolly, MD
    Professor, Department of Radiation Oncology
    Chief of Brachytherapy Services
    Associate Chair of Community Practices
    Associate Medical Director, UMHS Strategic Planning and Business Development
    University of Michigan
    Ann Arbor, Michigan

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Varian Medical Systems Inc.

    Billy Wiseman Loo Jr, MD, PhD
    Professor, Thoracic Radiation Oncology
    Program Leader
    Department of Radiation Oncology
    Stanford University School of Medicine
    Stanford, California

    Advisory Committee: Varian Medical Systems Inc; Other: Founder and board member of TibaRay Inc.

    Jyoti D Patel, MD
    Professor of Medicine
    Director, Thoracic Oncology
    The University of Chicago
    Chicago, Illinois

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Takeda Oncology.

    RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: November 2019
    Expiration date: November 2020

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Select publications